978 related articles for article (PubMed ID: 16429394)
101. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
Zhang R; Zhang H; Wei H; Luo X
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
[TBL] [Abstract][Full Text] [Related]
102. Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma.
Kamal M; Shaaban AM; Zhang L; Walker C; Gray S; Thakker N; Toomes C; Speirs V; Bell SM
Breast Cancer Res Treat; 2010 Jun; 121(3):555-63. PubMed ID: 19669408
[TBL] [Abstract][Full Text] [Related]
103. [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].
Mainka P; Kahlert S; Kirchner T; Mayr D; Diebold J
Pathologe; 2008 Nov; 29 Suppl 2():363-9. PubMed ID: 18807040
[TBL] [Abstract][Full Text] [Related]
104. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
[TBL] [Abstract][Full Text] [Related]
105. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
Meenakshi A; Manoharan V
Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
[TBL] [Abstract][Full Text] [Related]
106. Male breast cancer: pathological and immunohistochemical features.
Willsher PC; Leach IH; Ellis IO; Bell JA; Elston CW; Bourke JB; Blamey RW; Robertson JF
Anticancer Res; 1997; 17(3C):2335-8. PubMed ID: 9245247
[TBL] [Abstract][Full Text] [Related]
107. Breast cancer in women aged 35 and under: prognosis and survival.
Jmor S; Al-Sayer H; Heys SD; Payne S; Miller I; Ah-See A; Hutcheon A; Eremin O
J R Coll Surg Edinb; 2002 Oct; 47(5):693-9. PubMed ID: 12463710
[TBL] [Abstract][Full Text] [Related]
108. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
[TBL] [Abstract][Full Text] [Related]
109. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance.
Michels JJ; Duigou F; Marnay J; Henry-Amar M; Delozier T; Denoux Y; Chasle J
Cancer; 2003 Mar; 97(6):1376-86. PubMed ID: 12627500
[TBL] [Abstract][Full Text] [Related]
110. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer.
Stein T; Price KN; Morris JS; Heath VJ; Ferrier RK; Bell AK; Pringle MA; Villadsen R; Petersen OW; Sauter G; Bryson G; Mallon EA; Gusterson BA
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6872-9. PubMed ID: 16203777
[TBL] [Abstract][Full Text] [Related]
111. Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions.
Tan PH; Lui GG; Chiang G; Yap WM; Poh WT; Bay BH
Histopathology; 2004 Oct; 45(4):343-51. PubMed ID: 15469472
[TBL] [Abstract][Full Text] [Related]
112. Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in invasive micropapillary carcinoma of the breast.
Gong Y; Sun X; Huo L; Wiley EL; Rao MS
Histopathology; 2005 Jan; 46(1):24-30. PubMed ID: 15656882
[TBL] [Abstract][Full Text] [Related]
113. Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast.
Jitsuiki Y; Hasebe T; Tsuda H; Imoto S; Tsubono Y; Sasaki S; Mukai K
Mod Pathol; 1999 May; 12(5):492-8. PubMed ID: 10349987
[TBL] [Abstract][Full Text] [Related]
114. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
Yu L; Yang WT; Cai X; Lu HF; Fan YZ; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
[TBL] [Abstract][Full Text] [Related]
115. [Malignant myoepithelioma associated with in situ and invasive ductal carcinoma. Description of a case and review of the literature].
Scarpellini F; Usellini L; Foschini MP
Pathologica; 1997 Aug; 89(4):420-4. PubMed ID: 9471611
[TBL] [Abstract][Full Text] [Related]
116. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
117. [Myoepithelial differentiation markers in salivary gland neoplasia].
Scarpellini F; Marucci G; Foschini MP
Pathologica; 2001 Dec; 93(6):662-7. PubMed ID: 11785118
[TBL] [Abstract][Full Text] [Related]
118. Clinical presentation and long-term outcome of pure myoepithelial carcinoma of the breast.
Behranwala KA; Nasiri N; A'Hern R; Gui GP
Eur J Surg Oncol; 2004 May; 30(4):357-61. PubMed ID: 15063887
[TBL] [Abstract][Full Text] [Related]
119. Molecular phenotypes of matched in situ and invasive components of breast carcinomas.
Martins D; Sousa B; Lopes N; Gomes M; Veronese L; Albergaria A; Paredes J; Schmitt F
Hum Pathol; 2011 Oct; 42(10):1438-46. PubMed ID: 21450330
[TBL] [Abstract][Full Text] [Related]
120. Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma.
Imai J; Ghazizadeh M; Naito Z; Asano G
Anticancer Res; 2001; 21(2B):1327-34. PubMed ID: 11396208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
